EUVIMEDEUVIMED entdecken
Crossref

Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Vicki L. Ellingrod, PharmD, BCPP, Jeffrey R. Bishop, PharmD, MS, Jessica Moline, BS, Ying-Chi Lin, MS, and Del D. Miller, PharmD und 1 weitere

Psychopharmacology Bulletin · 12.08.2025 · 40 (1) · 57-62

DOI: 10.64719/pb.4131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 12.08.2025. Verfasst von Vicki L. Ellingrod und 12 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of the current investigation was to determine the relationship between polymorphisms of the leptin system (leptin gene and leptin receptor) and olanzapine-induced weight gain in persons with schizophrenia.

Design

Pharmacogenetic association reanalysis of a longitudinal, open-label, six-week, fixed-dose trial of olanzapine response and adverse effects. Subjects: Thirty-seven males and females with clinically symptomatic schizophrenia (age, 23–52) meeting DSM-IV criteria.

Measurements

Baseline and endpoint weight, BMI, olanzapine dose, plasma levels, and psychopathology measures were completed in a prior study. These subjects were subsequently genotyped for the –1548 G/A polymorphism of the leptin gene and the Q223R polymorphism of the leptin receptor. The relationship between alleles at each locus, olanzapine plasma levels, and percent change in body mass index (BMI) from baseline were conducted.

Results

Genotypes and alleles for each locus were not individually associated with olanzapine-induced weight gain in this study population. Changes in BMI from baseline increased significantly in persons with olanzapine plasma levels ≥20.6 ng/mL for subjects carrying at least one G allele at both candidate loci compared to those who did not have a G allele at each (P = 0.049).

Conclusions

This study suggests that genetic variability in the leptin gene and leptin receptor may predispose some individuals to excessive weight gain from increased exposure to olanzapine. Psychopharmacology Bulletin. 2007;40(1):57-62.

Zitieren

APA

Ellingrod, V. L., PharmD, BCPP, Bishop, J. R., PharmD, MS, Moline, J., BS, Lin, Y., MS, Miller, A. D. D., PharmD, & MD (2025). Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia. Psychopharmacology Bulletin, 40(1), 57-62. https://doi.org/10.64719/pb.4131

Vancouver

Ellingrod VL, PharmD, BCPP, Bishop JR, PharmD, MS, et al. Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia. Psychopharmacology Bulletin. 2025;40(1):57-62. doi:10.64719/pb.4131

BibTeX
@article{Ellingrod2025,
  author = {Ellingrod, Vicki L. and PharmD and BCPP and Bishop, Jeffrey R. and PharmD and MS and Moline, Jessica and BS and Lin, Ying-Chi and MS and Miller, and Del D. and PharmD and MD},
  title = {Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia},
  journal = {Psychopharmacology Bulletin},
  year = {2025},
  volume = {40},
  number = {1},
  pages = {57--62},
  doi = {10.64719/pb.4131}
}
Kostenlos starten →